Literature DB >> 7908892

CD8+ T-cell subsets defined by expression of CD45 isoforms differ in their capacity to produce IL-2, IFN-gamma and TNF-beta.

D Adamthwaite1, M A Cooley.   

Abstract

Expression of different isoforms of CD45, the leucocyte common antigen (LCA), on T-cell subsets has permitted distinctions between the functional activities of subpopulations within the major CD4+ T-cell subset. With respect to cytokine production, the expression on CD4+ cells of CD45RA, a high molecular weight isoform, defines a population which produces only interleukin-2 (IL-2) and tumour necrosis factor-beta (TNF-beta) in quantity, with peak production of IL-2 occurring after 24-48 hr stimulation, while the CD4+ population bearing high levels of CD45RO, a low molecular weight isoform, can produce a wide range of cytokines within 24 hr of activation. The literature is conflicting on the capacities for cytokine production of CD8+ subsets divided on the basis of either CD45RA or CD45RO expression. The aim of this study was to attempt to clarify this area by determining the amount and kinetics of production of IL-2, interferon-gamma (IFN-gamma) and TNF-beta in CD8+ cells separated on the basis of both CD45RA and CD45RO isoform expression. The results showed that CD8+ CD45RA- and CD8+ CD45RO+ T lymphocytes produce significantly more of all three cytokines than do CD8+ CD45RA+ or CD8+ CD45RO- T cells. The kinetics for IFN-gamma and TNF-beta production were similar for both subsets, while IL-2 production was delayed by approximately 3 hr in the CD8+ CD45RO- population as compared to the CD8+ CD45RO+ subset. It is suggested that some of the confusion over cytokine production by these CD8+ subsets may be attributable to different conditions for isolation causing pre-activation of positively selected populations. It is also suggested that while CD8+ CD45RA+ cells are shown to acquire CD45RO upon activation, as do CD4+ CD45RA+ cells, the results of the present study argue for a different relationship between CD8+ subsets separated on the basis of CD45 isoform expression than between the corresponding CD4+ subsets.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908892      PMCID: PMC1422313     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1.

Authors:  S H Smith; M H Brown; D Rowe; R E Callard; P C Beverley
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

2.  Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes.

Authors:  G R Woollett; A N Barclay; M Puklavec; A F Williams
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

3.  Cellular events during memory T-cell activation in vitro: the UCHL1 (180,000 MW) determinant is newly synthesized after mitosis.

Authors:  A N Akbar; A Timms; G Janossy
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

4.  Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase.

Authors:  J Mestan; M Brockhaus; H Kirchner; H Jacobsen
Journal:  J Gen Virol       Date:  1988-12       Impact factor: 3.891

5.  Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites.

Authors:  L Schofield; J Villaquiran; A Ferreira; H Schellekens; R Nussenzweig; V Nussenzweig
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

6.  Role of specific cytotoxic lymphocytes in cellular immunity against murine cytomegalovirus.

Authors:  M Ho
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

7.  Expression of interleukin 5 by the CD4+CD45R0+ subset of human T cells.

Authors:  W A Sewell; J E Valentine; M A Cooley
Journal:  Growth Factors       Date:  1992       Impact factor: 2.511

8.  CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells.

Authors:  J A Ledbetter; N K Tonks; E H Fischer; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

9.  Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies.

Authors:  M Dohlsten; G Hedlund; H O Sjögren; R Carlsson
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

10.  Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens.

Authors:  M Streuli; L R Hall; Y Saga; S F Schlossman; H Saito
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  5 in total

1.  T cells with a quiescent phenotype (CD45RA+) are overabundant in the blood and involuted lymphoid tissues in wasting protein and energy deficiencies.

Authors:  B Woodward; L Hillyer; K Hunt
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  Induction of selective anergy by toxic shock syndrome toxin-1 in CD8+ T cells.

Authors:  Y X Zhao; R Holmdahl; A Tarkowski
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

3.  The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.

Authors:  Hongkai Yan; Yaqi Li; Xiaoyu Wang; Juanjuan Qian; Midie Xu; Junjie Peng; Dan Huang
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

4.  MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome.

Authors:  Chang-Yien Chan; Lourdes Paula Resontoc; Md Abdul Qader; Yiong-Huak Chan; Isaac Desheng Liu; Perry Yew-Weng Lau; Mya Than; Wee-Song Yeo; Alwin Hwai-Liang Loh; Puay-Hoon Tan; Changli Wei; Jochen Reiser; Subhra K Biswas; Kar-Hui Ng; Hui-Kim Yap
Journal:  Pediatr Res       Date:  2019-01-15       Impact factor: 3.756

5.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.